[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369488-105":59,"doc-detail-369488-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","paclitaxel-interferons-and-functional-reprogramming-of-tumor-associated-macrophages-in-optimized-chemoimmunotherapy","Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemoimmunotherapy","","Immune checkpoint inhibition targeting PD-1 prevents the loss of activated cytotoxic T lymphocytes, yet efficacy remains limited in many “cold” tumors that lack CTL infiltration. Metastatic triple-negative breast cancer responds to PD-1 blockade in only a small fraction of patients, and chemotherapy sensitization mechanisms are incompletely understood. Evidence highlights paclitaxel-driven TLR4 signaling and type-1/type-2 interferon activation in tumor-associated macrophages, promoting local M2-to-M1 transition and enhanced antigen cross-presentation. These insights suggest new strategies to improve chemo-immunotherapy for metastatic and potentially early TNBC and other taxane-sensitive cancers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/paclitaxel-interferons-and-functional-reprogramming-of-tumor-associated-macrophages-in-optimized-chemoimmunotherapy/369488/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/paclitaxel-interferons-and-functional-reprogramming-of-tumor-associated-macrophages-in-optimized-chemoimmunotherapy/369488.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is PD-1 blockade less effective in “cold” tumors?","Question",{"text":113,"@type":114},"PD-1 inhibition relies on the presence of CTL activity in the tumor microenvironment. “Cold” tumors lack CTL infiltration, limiting checkpoint blockade effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What sensitization mechanism is proposed for paclitaxel in TNBC?",{"text":118,"@type":114},"Paclitaxel-driven TLR4 signaling activates type-1 and type-2 interferon pathways in tumor-associated macrophages, enabling local M2-to-M1 transition and enhancing tumor antigen cross-presentation.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the TLR4 pathway act as a double-edged sword in paclitaxel treatment?",{"text":122,"@type":114},"Paclitaxel/TLR4 activation can promote antitumor immunity via interferon-driven macrophage conversion, but parallel MyD88/NFκB signaling can also activate COX2/PGE2-mediated tumor-promoting effects and local immunosuppression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369488,1790828104,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":105,"preview_page_count":19,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Commentary  \n Paclitaxel, interferons and functional  \nreprogramming of tumor-associated macrophages in optimized chemoimmunotherapy  \nPawel Kalinski  ,1 Kathleen M Kokolus  ,2 Shipra Gandhi1  \nTo cite: Kalinski P, Kokolus KM, Gandhi S. Paclitaxel, interferonsand functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy. Journal for ImmunoTherapy of Cancer 2025;13:e010960 . doi:10 . 1136/ jitc-2024-010960  \nAccepted 24 April 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA 2Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA  \nCorrespondence to  \nDr Pawel Kalinski;  \n[pawel.kalinski@roswellpark.org](pawel.kalinski@roswellpark.org)  \nABSTRACT  \nImmune checkpoint inhibition (ICI) targeting programmed cell death protein-1 (PD1) prevents the elimination of activated cytotoxic T lymphocytes (CTLs) by programmed death-ligand 1/2-expressing cancer and myeloid cells in the tumor microenvironment (TME) . ICI has shown its effectiveness in many solid tumors, but it lacks activity against “cold” tumors which lack CTL infiltration, including most of the colon, prostate, lung and breast cancers. Metastatic triple-negative breast cancer (TNBC) responds to PD-1 blockade only in 5–20% cases. Chemotherapy has been shown to have a PD1-sensitizing effect in a fraction of patients with TNBC but the underlying mechanism and the reasoning behind its limitation to only a subset of patients are unknown. Recent data demonstrate the key roles played by paclitaxel-driven Toll-like receptor 4 (TLR4) signaling and the resulting activation of type-1 and type-2 interferon pathways in tumor-associated macrophages, resulting in local M2 to M1 transition and enhanced tumor antigen cross-presentation, in the paclitaxel-driven sensitization of “cold” tumors to ICI. These data and the known ability of the TLR4-activated MyD88-NFκB pathway to mobilize both antitumor and tumor-promoting events in the TME provide new tools to enhance the efficacy of chemo-immunotherapy for metastatic, and potentially early, TNBC and other taxane-sensitive cancers.  \nProgrammed cell death protein-1 (PD1)-programmed death-ligand 1 (PDL1)/PDL2 immune checkpoint inhibition (ICI) therapies, which prevent the apoptotic death of activated effector T cells in the tumor microenvironments (TMEs) have been the gamechangers in the clinical management of advanced (and increasingly early-stage) solid tumors, but their efficacy in several common cancers, such as lung, colon, prostate and breast cancers remain limited to patients with highly cytotoxic T lymphocyte (CTL)-infiltrated and more immunogenic tumors. Triple-negative breast cancer (TNBC), representing 10–20% of all breast cancers, lacks estrogen and progesterone receptors and HER2, showing a particularly aggressive character. However, TNBC has a limited yet  \nsignificant sensitivity to PD-1-blocking ICIs, which led to their Food and Drug Administration approval based on KEYNOTE 355 findings.1 The fraction of patients with metastatic TNBC benefitting from PD-1/PD-L1 blockade is limited to about 5% overall, which increases to 19–23% in patients with PD-L1-positive TME.2 In TNBC, PD1-blockade is currently approved in combination with chemotherapy, including taxanes and gemcitabine– carboplatin, which enhances the overall population response rate to over 20%, but the mechanism of synergistic action between these agents remains unclear, making it difficult to target the relevant stimulatory and/ or suppressive pathways to enhance the effectiveness of the paclitaxel-based and ICI-based chemo-immunotherapy.  \nKEY ROLE OF TLR4 IN PACLITAXEL-MOBILIZED CANCER IMMUNITY: A DOUBLE-EDGED SWORD  \nPaclitaxel is a tubulin-binding inhibitor of mitosis with complex positive and negative effects on the immune s","cbCaip50cEEfiTLs","https://ap.wps.com/l/cbCaip50cEEfiTLs","pdf",1270905,"English","# ABSTRACT\n## KEY ROLE OF TLR4 IN PACLITAXEL-MOBILIZED CANCER IMMUNITY: A DOUBLE-EDGED SWORD\n## Figure 1 Paclitaxel-driven TLR4 signaling and macrophage reprogramming","[{\"question\":\"Why is PD-1 blockade less effective in “cold” tumors?\",\"answer\":\"PD-1 inhibition relies on the presence of CTL activity in the tumor microenvironment. “Cold” tumors lack CTL infiltration, limiting checkpoint blockade effectiveness.\"},{\"question\":\"What sensitization mechanism is proposed for paclitaxel in TNBC?\",\"answer\":\"Paclitaxel-driven TLR4 signaling activates type-1 and type-2 interferon pathways in tumor-associated macrophages, enabling local M2-to-M1 transition and enhancing tumor antigen cross-presentation.\"},{\"question\":\"How does the TLR4 pathway act as a double-edged sword in paclitaxel treatment?\",\"answer\":\"Paclitaxel/TLR4 activation can promote antitumor immunity via interferon-driven macrophage conversion, but parallel MyD88/NFκB signaling can also activate COX2/PGE2-mediated tumor-promoting effects and local immunosuppression.\"}]","Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemoimmunotherapy | PDF",1790183000,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e3e12de0d7e632d84e6d09d96728a40.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83b81d0c628fe935375211be3d106410.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64a24a839b1e92df6d4f880413eaf460.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87a7c21932afab2711044149881177c5.webp",980,1306]